Health care organizations face a growing wave of cyberattacks and must implement strong defenses to protect patient data and ensure operational continuity.
Health care enterprises today are plagued by increasingly sophisticated cyberattacks. To combat cyber threats—the most common being hacking, ransomware, phishing, and supply chain attacks—health care organizations must proactively operationalize key risk mitigation strategies to shore up their cyber defenses.
The HIPAA Journal reported that 2023 saw a record 725 large health care security breaches reported to the US Department of Health and Human Services Office for Civil Rights, eclipsing the record of 720 health care security breaches set the previous year.1 As a result of these breaches, an average of 373,788 health care records were breached every day in 2023.
In late February, an attack on Change Healthcare (part of Optum, a UnitedHealth Group company) impacted the company’s pharmacy, medical claims, and payment systems. The outage left some doctors unable to check patients’ eligibility for treatment or prevented them from filling prescriptions electronically. The attack also extended to financial disruption for providers who were unable to receive reimbursements from insurers.
Suggestions to minimize the impact of these cyberattacks are detailed in the sidebar (right).
As cyberattacks evolve, health care organizations can protect patients and prevent operational disruptions by using these best practice risk mitigation strategies.
For the full article and more information visit, https://bit.ly/4afUVdT
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More